Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2018 | 03-2017 | 03-2016 | 03-2015 | 03-2014 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 377 | 353 | 161 | N/A | N/A |
| Income taxes - deferred | -310 | -298 | -865 | N/A | N/A |
| Accounts receivable | -46 | 190 | -153 | 280 | -200 |
| Other Working Capital | -476 | 425 | -226 | 314 | -452 |
| Other Operating Activity | -5,996 | -4,110 | -1,687 | -4,389 | -2,280 |
| Operating Cash Flow | $-6,451 | $-3,440 | $-2,770 | $-3,796 | $-2,932 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -51 | -14 | -39 | N/A | N/A |
| Net Acquisitions | N/A | 0 | -400 | N/A | N/A |
| Sale Of Investment | N/A | N/A | 0 | 625 | N/A |
| Purchase Sale Intangibles | 0 | -244 | -250 | N/A | N/A |
| Investing Cash Flow | $-51 | $-257 | $-689 | $625 | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 139 | -392 | 67 | N/A | N/A |
| Debt Issued | N/A | 0 | 2,550 | N/A | 0 |
| Common Stock Issued | 4,983 | 4,179 | 1,225 | 1,045 | 7,643 |
| Other Financing Activity | 3,630 | 1,019 | -394 | -582 | -1,151 |
| Financing Cash Flow | $8,752 | $4,806 | $3,448 | $463 | $6,492 |
| Exchange Rate Effect | -27 | 7 | N/A | N/A | N/A |
| Beginning Cash Position | 1,502 | 386 | 397 | 3,105 | 194 |
| End Cash Position | 3,726 | 1,502 | 386 | 397 | 3,755 |
| Net Cash Flow | $2,251 | $1,109 | $-11 | $-2,708 | $3,561 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,451 | -3,440 | -2,770 | -3,796 | -2,932 |
| Capital Expenditure | -51 | -257 | -289 | N/A | N/A |
| Free Cash Flow | -6,501 | -3,697 | -3,059 | -3,796 | -2,932 |